Celgene gets FDA nod for blood cancer drug combo Revlimid plus rituximab

This article was originally published here

Revlimid plus rituximab is claimed to be the FDA-approved combination treatment regimen for patients with these indolent forms of non-Hodgkin’s lymphoma (NHL), which does not include chemotherapy. Celgene

The post Celgene gets FDA nod for blood cancer drug combo Revlimid plus rituximab appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply